Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

ADC Therapeutics SA ADCT

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
19.64
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — 1 — — — — — —
Insider Ownership
36.11%

Capital & Financial Ratios

Market Cap
135.33
Revenue
79.58
Net Income
(96.91)
Free Cash Flow
(101.64)
Net Debt
(102.49)
Current Ratio
3.03
Debt/Equity
(0.51)
P/E ratio
0.00
P/S ratio
2.05
P/B ratio
0.00
Past 5Y EPS Growth
1.38%
This Y EPS Growth
32.14%
Next Y EPS Growth
10.86%
Next 5Y EPS Growth
38.34%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2019 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 278.60 250.87 261.34 219.11
Receivables 25.18 20.32 29.12 28.04
Inventory 16.18 2.25 4.18 4.93
Other 5.99 9.45 6.08 4.25
336.29 291.25 306.34 261.71
2023 2024 2025 Q'26
Payables 15.57 18.03 9.18 12.76
ST’ Debt — — 3.00 6.18
Other — — — —
67.67 80.47 70.16 86.33
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 20.85 19.25 — —
—
’25 23.03 18.84 16.43 23.06
81.36
’24 18.05 17.41 18.46 16.91
70.84
’23 18.99 19.28 14.49 16.79
69.56
’22 46.50 17.29 76.32 69.80
209.91
’21 — 3.76 13.15 17.01
33.92
’19 — 1.96 — —
2.34
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (29.71) (11.81) — —
—
’25 (56.33) (24.09) (29.63) (31.12)
(141.17)
’24 (44.09) (32.84) (25.04) (21.85)
(123.83)
’23 (15.39) (34.99) (36.67) (31.63)
(118.69)
’22 (33.88) (53.01) 2.20 (53.61)
(138.31)
’21 (55.15) (58.01) (58.59) (61.63)
(233.38)
’20 (32.10) (40.65) (44.29) (51.69)
(168.73)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (29.74) (11.81) — —
—
’25 (56.60) (24.09) (29.63) (30.46)
(140.78)
’24 (44.63) (32.87) (25.26) (21.94)
(124.70)
’23 (16.43) (36.22) (37.35) (31.96)
(121.90)
’22 (35.00) (53.82) 1.94 (53.84)
(140.72)
’21 (55.81) (60.86) (60.93) (62.16)
(239.75)
’20 (32.58) (40.80) (45.69) (52.47)
(171.54)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.21) (0.11) — —
—
’25 (0.36) (0.50) (0.30) (0.04)
(1.12)
’24 (0.56) (0.38) (0.42) (0.29)
(1.62)
’23 (0.74) (0.58) (0.58) (1.03)
(2.94)
’22 (0.22) (0.84) (0.65) (0.30)
(1.99)
’21 (0.67) (0.95) (0.93) (0.45)
(3.00)
’20 (0.65) (2.01) (0.29) (0.73)
(3.77)

Target Price Range

High
‡‡‡‡‡
‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 2.69 0.36 1.45 1.05 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 20.67 5.75 6.04 4.80 — — —
High Price
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 317 274 265 193 — — —
Employees
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.66 0.25 0.27 0.42 — — —
Revenue/Emp
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ 209.91 69.56 70.84 81.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 98.43% 96.36% 91.60% 92.87% — — —
Gross Margin
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (146.82) (195.42) (156.14) (141.61) — — —
EBT
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ (69.94%) (280.94%) (220.42%) (174.06%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (157.13) (240.05) (157.85) (142.62) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.39 3.27 3.28 1.88 — — —
Depreciation
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 2.69 0.85 0.73 0.64 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (1.99) (2.94) (1.62) (1.12) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.77) (1.45) (1.27) (1.11) — — —
Cash Flow/Sh
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.03) (0.04) (0.01) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.80) (1.49) (1.28) (1.11) — — —
Free CF/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.02 (1.81) (2.09) (1.46) — — —
Book Value/Sh
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 78.15 81.71 97.16 127.07 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— ‡‡‡ ‡‡‡ ‡‡‡ — ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— ‡‡‡ ‡‡‡ ‡‡‡ — ‡‡‡‡‡ 1.34 1.99 2.73 5.51 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ 3.53 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— ‡‡‡ ‡‡‡ ‡‡‡ — ‡‡‡‡‡ 0.36 (0.19) 0.99 3.72 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ (0.54) 0.11 (0.56) (2.15) — — —
EV/FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (138.31) (118.69) (123.83) (141.17) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.41) (3.22) (0.87) 0.40 ‡‡‡‡‡ — —
Capex
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (140.72) (121.90) (124.70) (140.78) ‡‡‡‡‡ — —
FCF
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 353.04 268.62 210.79 236.17 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 122.19 112.73 113.63 115.45 — — —
Total Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (204.25) (165.87) (137.23) (145.89) — — —
Net Debt
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 79.45 (148.25) (202.64) (185.83) — — —
Sh' Equity
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (28.34%) (56.77%) (46.65%) (44.22%) — — —
ROA
— ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (127.99%) 697.85% 89.97% 73.43% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

ADC Therapeutics (ADCT) exemplifies biotech’s high-wire act, with its antibody-drug conjugate (ADC) platform delivering Zynlonta’s FDA approval in 2021 amid explosive revenue growth to $210 million in 2022, only to plummet 67% to $69.6 million in 2023 following AstraZeneca’s rights return and sales shortfalls. The stock has mirrored this volatility, crashing over 90% from pandemic highs above $50 to recent lows around $1-6, underscoring execution risks in a sector prone to clinical and commercial pitfalls. Yet, stabilizing gross margins above 91% and a pipeline reboot with next-gen assets like ADCT-601 offer cautious glimmers of recovery.

Persistent losses deepen the downside concerns: EBT at -$156 million in 2024, with operating cash burn of -$124 million eroding a once-robust runway, compounded by share dilution to 97 million and negative shareholder equity of -$203 million—a stark balance sheet red flag signaling potential recapitalization needs. Liquidity remains a buffer, with negative net debt of -$137 million supporting R&D amid layoffs, but ROE under 1% and ROA at -47% highlight inefficient capital use in this loss-making growth story.

Analysts project revenue doubling to $149 million by 2027 alongside EPS improvement to -$0.68, fueling price targets implying 25-150% upside, betting on ADC sector tailwinds. No insider buying adds neutrality, but milestone dependency and biotech winters warn of sub-$1 risks if catalysts falter. For risk-averse investors, ADCT demands tight position sizing amid its pivot from promise to peril.

Read full commentary →

ADC Therapeutics SA (ADCT) Latest News

News by impact score

Fine-tune

27 Aug

4 , 4:42 PM
ADC Therapeutics encounters FDA setback but reduces losses. FDA setback creates major regulatory hurdle for ADC Therapeutics while loss reductions offer limited offset.

20 Aug

3 transcript www.fool.com, 3:49 PM
ADC Therapeutics SA held its Q2 2026 earnings call. Earnings call provides updates on financials and outlook with moderate market influence.

15 Aug

4 , 11:15 PM
ADC Therapeutics stock fair value declines after LOTIS 5 trial reshapes Zynlonta outlook. LOTIS 5 trial directly alters Zynlonta prospects and lowers ADCT fair value.

13 Aug

3 transcript app.moby.co, 8:25 PM
ADC Therapeutics SA held Q2 2026 earnings call covering financial results, operational updates and forward outlook. Quarterly earnings call delivers financial metrics and guidance that moderately influence near-term valuation and sentiment.

3 , 7:07 PM
ADC Therapeutics SA reported Q2 2026 earnings amid ongoing regulatory hurdles affecting operations and product timelines. Regulatory hurdles signal moderate effects on approvals and growth trajectory.

3 transcript www.marketbeat.com, 4:04 PM
ADC Therapeutics SA (ADCT) released Q2 earnings call highlights covering financial results, operational updates and strategic outlook. Quarterly earnings highlights offer moderate insight into financials and strategy that can sway near-term sentiment without guaranteeing major trajectory shifts.

3 , 7:30 AM
ADC Therapeutics SA reported second quarter 2026 financial results and provided operational updates. Quarterly financial results and operational updates affect valuation and near-term market perception.

6 Jul

4 , 12:00 PM
VERAXA bets its entire future on cancer therapy strategy linked to ADC Therapeutics SA (ADCT) product development and positioning. Company-wide strategic bet on ADCT cancer therapy signals major trajectory shift and investor sentiment change for ADCT.

27 Jun

3 , 5:08 AM
ADC Therapeutics (ADCT) stock fair value falls after LOTIS 5 results prompt analysts to revise views downward on the company's valuation and prospects. LOTIS 5 data directly lowers fair value estimates and shifts analyst sentiment on ADCT performance.

24 Jun

4 PR Newswire, 7:30 AM
ADC Therapeutics SA announces strategic reorganization to support ZYNLONTA growth opportunities and regulatory priorities. Strategic reorganization targets ZYNLONTA expansion and regulatory focus, positioning company for substantial future shifts.

3 stocktwits.com, 9:13 AM
ADC Therapeutics SA plans to cut about 17% of its staff amid ongoing operational adjustments. Workforce reduction signals cost-cutting that may affect near-term operations and sentiment but is unlikely to fundamentally shift long-term trajectory.

7 Jun

4 Simply Wall St., 8:17 PM
ADC Therapeutics (ADCT) shares plunged 69.7% after mixed LOTIS-5 ZYNLONTA trial data, raising doubts on the prior bull case. Mixed ZYNLONTA trial data directly hit ADC Therapeutics' lead product outlook and triggered a major valuation reset.

4 Jun

4 Zacks, 10:43 AM
ADC Therapeutics SA stock plunges on safety concerns despite positive lymphoma data. Safety concerns risk halting ADCT product development and triggering sustained market selloff.

4 www.biopharmadive.com, 5:27 AM
ADC Therapeutics SA shares decline on safety concerns for its blood cancer drug. Safety concerns for ADC Therapeutics' lead blood cancer drug risk regulatory setbacks and erode market confidence.

3 Jun

4 , 4:05 PM
ADC Therapeutics announced results from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA combined with Rituximab in relapsed or refractory diffuse large B-cell lymphoma. Phase 3 results for lead asset ZYNLONTA directly determine regulatory path and commercial outlook.

4 May

4 transcript www.fool.com, 7:05 PM
ADC Therapeutics SA (ADCT) released its Q4 2025 earnings call transcript detailing financial results, operational updates, and forward-looking guidance. Q4 earnings transcripts disclose financial performance, pipeline developments, and strategic plans that significantly impact future market performance and investor sentiment.

4 transcript www.fool.com, 4:23 PM
ADC Therapeutics SA (ADCT) released Q1 2026 earnings call transcript detailing financial results, pipeline updates, and forward guidance. Q1 2026 earnings transcript covers financial performance, clinical progress, and strategic outlook with potential to drive major shifts in ADCT's market trajectory.

4 www.marketbeat.com, 9:39 AM
ADC Therapeutics Q1 earnings call highlights financial results, operational progress, pipeline updates, and forward guidance amid ongoing clinical trials and commercialization efforts. Q1 earnings highlights cover financial performance, pipeline advancements, and strategic outlook, significantly impacting investor sentiment and stock trajectory.

3 app.moby.co, 4:44 PM
ADC Therapeutics S.A. Q1 2026 earnings call summary covers financial results, pipeline updates, and forward guidance for the oncology-focused biotech firm. Q1 earnings summary reveals quarterly financials and outlook, moderately affecting investor sentiment and stock trajectory.

3 Zacks, 8:35 AM
ADC Therapeutics SA (ADCT) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite net loss moderately bolsters financial outlook and investor sentiment.

3 PR Newswire, 7:30 AM
ADC Therapeutics SA reported first quarter 2026 financial results and provided operational updates. Quarterly financial results and operational updates moderately impact financial performance and investor sentiment.

26 Mar

4 www.marketbeat.com, 8:33 PM
ADC Therapeutics plans ZYNLONTA expansion as LOTIS-5 trial data approaches presentation at H.C. Wainwright conference. ZYNLONTA expansion and impending LOTIS-5 data signal major strategic advancements boosting ADCT's growth prospects.

18 Mar

4 Insider Monkey, 5:31 PM
ADC Therapeutics (ADCT) reported 2025 revenue of $73.6 million with a cash runway extending into 2028. Strong revenue figure and cash runway into 2028 enhance financial stability and support sustained operations and investor confidence.

10 Mar

4 GuruFocus.com, 5:01 PM
ADC Therapeutics SA (ADCT) reported revenue growth and strategic advancements in its Q4 2025 earnings call highlights. Revenue growth and strategic initiatives represent major positive developments that could significantly enhance ADCT's financial trajectory and investor sentiment.

4 www.marketbeat.com, 11:17 AM
ADC Therapeutics SA (ADCT) released Q4 earnings call highlights, detailing financial results, pipeline progress, and strategic outlook. Q4 earnings call highlights cover financial performance, product updates, and guidance that could significantly shape investor sentiment and company trajectory.

4 PR Newswire, 7:30 AM
ADC Therapeutics SA reported fourth quarter and full year 2025 financial results, including key revenue figures, cash position updates, and pipeline progress, alongside an operational update on clinical trials and regulatory milestones. Quarterly and annual financial results with operational updates directly affect financial performance, pipeline expectations, and investor sentiment.

3 Zacks, 8:35 AM
ADC Therapeutics SA (ADCT) reported a Q4 loss while surpassing revenue estimates. Q4 revenue beat despite loss moderately impacts financial perception and stock sentiment short-term.

23 Feb

3 PR Newswire, 7:15 AM
ADC Therapeutics SA announced an amendment to its financing agreement with HealthCare Royalty, adjusting terms to enhance financial flexibility. Amending the royalty financing agreement affects ADC Therapeutics' cash flow and financial stability without fundamentally altering its core operations.

30 Jan

4 Zacks, 9:40 AM
ADC Therapeutics SA (ADCT) has shown strong performance this year, outperforming many other medical stocks. The company's advancements in its drug pipeline and positive clinical trial results have contributed to its stock price increase. Investors are optimistic about its future prospects, particularly in the oncology sector, as ADC Therapeutics continues to innovate and expand its market presence. Significant advancements in drug development and positive market reception are likely to impact future performance.

13 Jan

3 Zacks, 9:40 AM
ADC Therapeutics SA (ADCT) has been underperforming compared to other medical stocks this year, raising concerns among investors. The company's stock price has seen fluctuations, and analysts are closely monitoring its performance in relation to broader market trends. Factors such as product pipeline developments and competitive positioning are influencing market sentiment towards ADCT. Investors are advised to consider these dynamics when evaluating the company's future prospects. Moderate fluctuations in stock performance and competitive positioning are influencing investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us